Long noncoding RNA (lncRNA) for clinical risk assessment of preeclampsia (PE) and application of lncRNA

A clinical risk assessment, long-chain non-coding technology, applied in the medical field, can solve problems such as few drugs and heavy economic burden, and achieve strong feasibility and simple and convenient sample acquisition

CN112210599AActive Publication Date: 2021-01-12GENERAL HOSPITAL OF NINGXIA MEDICAL UNIV +1
2 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2021-01-12

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Long noncoding RNA (lncRNA) for clinical risk assessment of preeclampsia (PE) comprises the following steps: consulting and analyzing medical record data of a patient, and collecting placenta tissuesof a normal pregnant woman and a preeclampsia pregnant woman; preparing placenta tissue paraffin sections, and observing placenta tissue structure changes through placenta tissue pinus massoniana staining; carrying out bioinformatics analysis on the structure of the damage induced noncoding (DINO) RNA; extracting placenta tissue lncRNA, and detecting expression change of the DINO RNA; culturing human placenta trophoblasts, and screening DINO RNA interference fragments; after interfering with the DINO RNA, detecting the protein expression change of matrix metalloproteinase 2 (MMP-2); and afterinterfering with the DINO RNA, detecting the cell migration ability through a scratch test, and detecting cell invasion change through an invasion test. The lncRNA is used for preventing and diagnosing the PE. Samples are simple and convenient to obtain, no trauma is caused to a patient, and the feasibility is higher.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of medical technology, and relates to a long-chain non-coding RNA used for clinical risk assessment of preeclampsia and an application thereof. Background technique

[0002] Preeclampsia (PE) is a common pregnancy complication that causes multiple organ and system damage in pregnant women. It is one of the idiopathic diseases of pregnancy. Urine is the main clinical manifestation, and in severe cases, systemic dysfunction may occur. It is an important cause of maternal mortality and perinatal death. Blood, urine, fundus examination, etc. are commonly used diagnostic methods for preeclampsia, but such methods are traditional, mainly relying on the characteristic clinical manifestations of the disease for diagnosis, but usually when the diagnosis is clear, the gestational age is usually relatively large. In terms of treatment, at present, only symptomatic treatment can be used to relieve symptoms. Due to the particular...

Examples

Embodiment Construction

[0035] The technical scheme of the present invention will be described in detail below in conjunction with the accompanying drawings and specific embodiments.

[0036]The long-chain non-coding RNA used for clinical risk assessment of preeclampsia, the specific implementation steps are as follows:

[0037] 1 Material preparation

[0038] 1.1 Materials and reagents: Human placental trophoblast cell line HTR-8 / SVneo (human chorionic trophoblast cells) (China, Shanghai Ruilu Biotechnology Co., Ltd.); fetal bovine serum, RPMI 1640 medium (Australia, Gibco company) ; penicillin, streptomycin, trypsin digestion solution, NP-40 (China, Beyontian Institute of Biotechnology); Masson staining kit, PMSF (China, Beijing Suolaibao Technology Co., Ltd.); MMP-2 (matrix metalloproteinase 2) Antibody (UK, Abcam Company), β-actin (β-actin) antibody, horseradish peroxidase-labeled secondary antibody (China, Beijing Jinqiao Co., Ltd.); skimmed milk powder (USA, BD Company); cDNA kit, RT-qPCR (re...